Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01414595
Official study title

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

Study summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies tissue samples from patients with non-small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedDNA analysis and DNA methylation analysis

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 27, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?11 U.S. locations

Locations may change over time.

Who runs it?Alliance for Clinical Trials in Oncology

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Alliance for Clinical Trials in Oncology
Interventions being studied
Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient must have been registered to CALGB 140202.
  • Tumor histology should be either primary adenocarcinoma or squamous cell carcinoma of the lung.
  • Patients are eligible for this study if their samples from CALGB 140202 are available.
  • All living patients must sign the CALGB 151107 consent form to be eligible for this trial.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical CenterLos Angeles, California
  • Tunnell Cancer Center at Beebe Medical CenterLewes, Delaware
  • CCOP - Christiana Care Health ServicesNewark, Delaware
  • Greenebaum Cancer Center at University of Maryland Medical CenterBaltimore, Maryland
  • Union Hospital of Cecil CountyElkton, Maryland
  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint LouisSt Louis, Missouri
  • Cancer Institute of New Jersey at Cooper - VoorheesVoorhees Township, New Jersey
  • Roswell Park Cancer InstituteBuffalo, New York
  • Duke Cancer InstituteDurham, North Carolina
  • Rhode Island Hospital Comprehensive Cancer CenterProvidence, Rhode Island
  • Miriam HospitalProvidence, Rhode Island

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 27, 2017. Always confirm current availability with the study team.

View original record ↗